Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding

BackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target. Traditional non-blocking antagonists often disrupt immune homeostasis by excessively suppressing Treg cell function when blocking the...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Liang Huang, Chao Kong, Yuhao Hu, Michael Zhang, Shuangqi Li, Wanjing Wang, Hui Guan, Mei Ling Lim, Zhen Zhang, Wenhai Zhang, Hailiang Zheng, Xintian Yan, Xinglu Sun, Pan Lei, Shanshan Dai, Wenrong Wang, Linlin Lu, Junma Zhou, Shilong Fan, Guojun Lang
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2025-12-01
سلاسل:	Frontiers in Immunology
الموضوعات:	tumor necrosis factor receptor 2 nanobody-161 TNFα T cells antibody-dependent cell-mediated cytotoxicity
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1694313/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!